Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors.
Journal article, 2015

REarranged during Transfection (RET) is a transmembrane receptor tyrosine kinase required for normal development and maintenance of neurons of the central and peripheral nervous systems. Deregulation of RET and hyperactivity of the RET kinase is intimately connected to several types of human cancers, most notably thyroid cancers, making it an attractive therapeutic target for small-molecule kinase inhibitors. Novel approaches, allowing external control of the activity of RET, would be key additions to the signal transduction toolbox. In this work, photoswitchable RET kinase inhibitors based on azo-functionalized pyrazolopyrimidines were developed, enabling photonic control of RET activity. The most promising compound displays excellent switching properties and stability with good inhibitory effect towards RET in cell-free as well as live-cell assays and a significant difference in inhibitory activity between its two photoisomeric forms. As the first reported photoswitchable small-molecule kinase inhibitor, we consider the herein presented effector to be a significant step forward in the development of tools for kinase signal transduction studies with spatiotemporal control over inhibitor concentration in situ.

Author

Ruben Ferreira

Chalmers, Chemistry and Chemical Engineering

Jesper Nilsson

Chalmers, Chemistry and Chemical Engineering, Chemistry and Biochemistry

Carlos Solano

University of Gothenburg

Joakim Andreasson

Chalmers, Chemistry and Chemical Engineering, Chemistry and Biochemistry

Morten Grötli

University of Gothenburg

Scientific Reports

2045-2322 (ISSN) 20452322 (eISSN)

Vol. 5 artikel nr 9769- 9769

Photochromic Systems for Solid State Molecular Electronic Devices and Light-Activated Cancer Drugs (PHOTOCHROMES)

European Commission (EC) (EC/FP7/203952), 2008-09-01 -- 2013-08-31.

Subject Categories

Chemical Sciences

DOI

10.1038/srep09769

PubMed

25944708

More information

Latest update

3/2/2022 3